A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response

Research output: Contribution to journalArticle

Abstract

The search for novel prognostic and predictive parameters in breast carcinoma is relentless. The new technological advances in gene expression profiling and in mutational analysis will hopefully prove to be clinically useful in informing the choice for the systemic therapy. For the time being, we are still relying in established immunohistochemical markers, namely estrogen and progesterone receptors, HER2 and Ki67. Advances in the harmonization of pre-analytical, analytical and interpretative variables may improve accuracy and reproducibility of the results.

Original languageEnglish
Pages (from-to)S23-S25
JournalBreast
Volume24
DOIs
Publication statusPublished - Nov 1 2015

Keywords

  • Estrogen receptors
  • HER2
  • Ki67
  • Molecular profiling
  • Progesterone receptors
  • Prognostic parameters

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response'. Together they form a unique fingerprint.

Cite this